Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer

NCT04993014 is registered in ClinicalTrials.gov with AC Camargo Cancer Center as lead sponsor.

NCT NCT04993014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04993014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer
Lead sponsor
AC Camargo Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2021
Completion date
April 30, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, circulating tumor cell, her2-positive breast cancer